In massive, multi-billion-dollar corporate consolidations like Novartis's twelve-billion-dollar acquisition of Avidity Biosciences, the strategic execution relies heavily on a consortium of elite financial advisors, top-tier global investment banks, and specialized corporate law firms. While initial press releases often focus on the scientific synergies and financial premiums of the transaction, pharmaceutical giants like Novartis routinely retain the services of premier Wall Street institutions—such as Goldman Sachs, Centerview Partners, Morgan Stanley, or J.P. Morgan—to provide comprehensive fairness opinions, structural financial modeling, and risk assessments. Simultaneously, elite multinational legal practices are deployed to navigate the incredibly complex labyrinth of international antitrust regulations, intellectual property transfers, and federal regulatory approvals required by agencies like the Federal Trade Commission to ensure the massive healthcare acquisition closes successfully.